Showing results (1-10 of 28) with videos related to

Sort By:
Pageof 3
Molecular Biology Reports|January 14, 2022
Lower RNA expression of ALDH1A1 distinguishes the favorable risk group in acute myeloid leukemiaGarrett M Dancik, Ioannis F Voutsas, Spiros Vlahopoulos
Frontiers in Bioscience (Scholar Edition)|March 23, 2022
Aldehyde Dehydrogenase Enzyme Functions in Acute Leukemia Stem CellsGarrett M Dancik, Ioannis F Voutsas, Spiros Vlahopoulos
Cancer Immunology, Immunotherapy : CII|September 20, 2011
Ontak reduces the immunosuppressive tumor environment and enhances successful therapeutic vaccination in HER-2/neu-tolerant miceAngelos D Gritzapis, Ioannis F Voutsas, Constantin N Baxevanis
Immunotherapy|May 4, 2013
Toll-like receptor agonists: current status and future perspective on their utility as adjuvants in improving anticancer vaccination strategiesConstantin N Baxevanis, Ioannis F Voutsas, Ourania E Tsitsilonis
Cellular Immunology|January 22, 2016
A flow cytometric approach for studying alterations in the cytoplasmic concentration of calcium ions in immune cells following stimulation with thymic peptidesNikos E Papaioannou, Ioannis F Voutsas, Pinelopi Samara, et al.
Investigational New Drugs|September 8, 2010
Combined treatment with bevacizumab and standard chemotherapy restores abnormal immune parameters in advanced colorectal cancer patientsNikolaos Tsavaris, Ioannis F Voutsas, Christos Kosmas, et al.
Cancer Research|March 18, 2010
Peptide vaccination breaks tolerance to HER-2/neu by generating vaccine-specific FasL(+) CD4(+) T cells: first evidence for intratumor apoptotic regulatory T cellsAngelos D Gritzapis, Ioannis F Voutsas, Eftychia Lekka, et al.
Expert Review of Molecular Diagnostics|October 28, 2014
Immune biomarkers: how well do they serve prognosis in human cancers?Constantin N Baxevanis, Eleftheria A Anastasopoulou, Ioannis F Voutsas, et al.
Immunotherapy|July 20, 2010
HER-2/neu as a target for cancer vaccinesConstantin N Baxevanis, Ioannis F Voutsas, Angelos D Gritzapis, et al.
Oncoimmunology|September 14, 2016
MHC class II tetramer analyses in AE37-vaccinated prostate cancer patients reveal vaccine-specific polyfunctional and long-lasting CD4(+) T-cellsEleftheria A Anastasopoulou, Ioannis F Voutsas, Michael Papamichail, et al.
Pageof 3